High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study.

[1]  F. Mandelli,et al.  Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies , 2000, Leukemia.

[2]  F. Mandelli,et al.  High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study , 2000, Bone Marrow Transplantation.

[3]  F. Lo Coco,et al.  CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Lawson,et al.  Use of idarubicin in pre-transplant conditioning in children with high-risk acute leukaemia , 1999, Bone Marrow Transplantation.

[5]  F. Gherlinzoni,et al.  Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells , 1999, Bone Marrow Transplantation.

[6]  H. Rugo,et al.  Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report , 1998, Bone Marrow Transplantation.

[7]  N. Gorin.  Autologous stem cell transplantation in acute myelocytic leukemia. , 1998, Blood.

[8]  T. Witte,et al.  Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission , 1998, Bone Marrow Transplantation.

[9]  G Mele,et al.  Fludarabine, cytarabine, and G‐CSF (FLAG) for the treatment of poor risk acute myeloid leukemia , 1998, American journal of hematology.

[10]  Keith Wheatley,et al.  Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.

[11]  P. Wernet,et al.  Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patients. , 1997, Leukemia.

[12]  C. Sawyers,et al.  Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission , 1997, Leukemia.

[13]  F. Preijers,et al.  Outcome of transplantation for standard‐risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen , 1997, British journal of haematology.

[14]  M. Vignetti,et al.  BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. , 1996, Bone marrow transplantation.

[15]  J. Niland,et al.  In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Reiffers,et al.  A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. , 1996, Leukemia.

[17]  F. Ferrara,et al.  Simultaneous occurrence of tetrasomy 21 and trisomy 8 in a patient with early blastic metamorphosis of chronic myeloproliferative disorder , 1995, American journal of hematology.

[18]  M. Labopin,et al.  One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. , 1994, Blood.

[19]  R. Gingrich,et al.  Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. , 1994, Blood.

[20]  H. Rugo,et al.  Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen , 1993 .

[21]  F. Mancini,et al.  Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. , 1992, Leukemia.

[22]  A. Bartolucci,et al.  A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Richard J. Jones,et al.  Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. , 1992, Blood.

[24]  P. Ritch,et al.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .

[25]  J. Klein,et al.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen , 1987 .

[26]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[27]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[29]  M. Labopin,et al.  Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis , 2000, Bone Marrow Transplantation.

[30]  H. Prentice,et al.  Understanding the mechanism of cure of acute myeloid leukemia by allogeneic bone marrow transplantation: toward the application of interleukin-2 in autologous bone marrow transplantation. , 1994, Journal of hematotherapy.

[31]  E. Gehan,et al.  Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. , 1988, Leukemia.